VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov 6, 2013) - Response Biomedical Corp. (RBM.TO)(RPBIF) ("Response") will release its third quarter 2013 financial results after the markets close on Wednesday, November 13, 2013.

Jeffrey L. Purvin, Chief Executive Officer, will host a conference call to discuss the Q3, 2013 financial results on November 13, 2013 at 2:00 p.m. PST (5:00 p.m. EST), shortly after the initial release. Also participating in the call will be Bill Adams, Chief Financial Officer.

The conference call will be webcast live and is also available by dialing 1- 877-643-7155 in North America or 1- 914-495-8552 for all other locations. The conference ID number is 98047304 and participants are encouraged to initiate their calls at least 10 minutes in advance of the 2:00 p.m. PST (5:00 p.m. EST) start time to ensure a timely connection.

The live webcast and earnings release will be accessible from our website: http://responsebio.com/investors/presentations. A replay of the conference call will also be available online approximately two hours after the call and for 90 days thereafter.

Response also announces that Mr. Purvin, will be presenting at the Canaccord Genuity Medical Technology & Diagnostics Forum to be held at the Westin Grand Central Hotel, New York, New York, on Thursday, November 14, 2013 at 9:00 a.m. EST. A link to the webcast will be made available on the day of the presentation and for 90 days thereafter at http://responsebio.com/investors/presentations. Additionally, Mr. Adams will be presenting at the Sachs Associates MedTech & Diagnostics Innovations Summit to be held at the Hyatt Regency Hotel, Dusseldorf, Germany on Thursday, November 21, 2013 at 4:15 p.m. CET.

About Response Biomedical Corp.

Response develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP^® Platform for clinical, biodefense and environmental applications. RAMP^® represents a unique paradigm in diagnostics that provides reliable laboratory quality results in minutes. The RAMP^® Platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, influenza A and B and RSV. In the non-clinical market, RAMP^® tests are currently available for the environmental detection of West Nile Virus and for Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.